|
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
RECRUITINGPhase 2Sponsored by Biomea Fusion Inc.
Actively Recruiting
PhasePhase 2
SponsorBiomea Fusion Inc.
Started2026-04-30
Est. completion2027-06
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
Locations20 sites
View on ClinicalTrials.gov →
NCT07502508
Summary
This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite GLP-1-based therapy.
Eligibility
Age: 18 Years – 75 YearsHealthy volunteers accepted
Key Inclusion Criteria: 1. Males or females, age ≥18 years and ≤75 years 2. Have been diagnosed with T2D 3. Taking FDA-approved GLP-1 based therapy (administered as subcutaneous injection) and have been treated with lifestyle management and 0 to 2 additional antihyperglycemic medications (metformin and/or SGLT2 inhibitor) with a stable dose of all medications for at least 3 months prior to screening 4. Have HbA1c ≥7.0 and ≤10.5% 5. Have a BMI 25 to 45 kg/m2 6. Female participants of childbearing potential must have a negative pregnancy test, must be non-lactating, must be willing to have additional pregnancy tests during the study, must agree to the sex and contraception requirements. 7. Willing and able to provide written, signed informed consent and be willing and able to comply with all study procedures and tests. Key Exclusion Criteria: 1. Have type 1 diabetes mellitus or a secondary form of diabetes 2. Have a history of diabetic ketoacidosis or hyperosmolar coma in the 6 months prior to screening 3. Have a history of severe hypoglycemia (defined by the occurrence of hypoglycemia symptoms requiring the assistance of another person for recovery) in the 6 months prior to screening or a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms as judged by the investigator 4. Have personal or family history (first-degree relative) of MEN1 or MEN2 or medullary thyroid carcinoma 5. Use of any of the following in the 3 months prior to screening: compounded GLP-1-based therapy, sulfonylureas, meglitinides, thiazolidinediones, alpha glucosidase inhibitor, DPP4I, bile acid sequestrants, dopamaine-2 agonists, amylin, or insulin
Conditions2
DiabetesType 2 Diabetes
Interventions1
Locations20 sites
Central Research Associates, LLC dba Flourish Research
Hope Clinical Research
Ark Clinical Research
Catalina Research Institute, LLC
Paradigm Clinical Research Centers, LLC
Find trials near these locations
Diabetes trials in Long BeachDiabetes trials in San DiegoDiabetes trials in Las VegasDiabetes trials in AustinDiabetes trials in DallasDiabetes trials in HoustonDiabetes trials in San AntonioAll trials in AlabamaAll trials in CaliforniaAll trials in FloridaAll trials in GeorgiaAll trials in NevadaAll trials in North CarolinaAll trials in OhioAll trials in TexasAll trials in Virginia
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorBiomea Fusion Inc.
Started2026-04-30
Est. completion2027-06
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
Locations20 sites
View on ClinicalTrials.gov →
NCT07502508